LBO — USC NORRIS CANCER HOSPITAL
IRR: 18.6% | MOIC: 2.35x
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
18.6%
IRR
2.35x
MOIC
$386.2M
Entry EV
$628.7M
Exit EV
$198.7M
Equity Invested
Sources & Uses
S&UTotal · $386.2M| Item | Amount | % | Distribution |
|---|---|---|---|
| Senior Debt | $150.0M | 38.8% | |
| Sub Debt | $37.5M | 9.7% | |
| Equity | $198.7M | 51.5% | |
| Enterprise Value | $374.9M | 97.1% | |
| Transaction Fees | $11.2M | 2.9% | |
| Total Uses | $386.2M | 100.0% |
Interpretation
INTAt 2.35x MOIC and 18.6% IRR over 5 years, this deal meets the 15-20% range — acceptable with operational upside.
Key drivers: Check the EBITDA bridge to identify highest-probability levers, the debt schedule for leverage trajectory, or the challenge solver to see what breaks the deal.
Returns Waterfall
WFL| Component | Value |
|---|---|
| Exit Ebitda | $59.9M |
| Exit Ev | $628.7M |
| Net Debt At Exit | $162.3M |
| Equity At Exit | $466.4M |
| Equity Invested | $198.7M |
| Total Value Created | $267.6M |
| Value From Growth | $235.0M |
| Value From Multiple | $18.7M |
| Value From Deleveraging | $25.2M |